A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT06568939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide. Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT06568939
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2025
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
- Last update posted
- Sep 7, 2026
2025 – 2028
United States locations
- U.S. sites
- 39
- U.S. states
- 21
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Center /ID# 276370 | Chandler | Arizona | 85224 | Recruiting |
| University of Arkansas for Medical Sciences /ID# 272923 | Little Rock | Arkansas | 72205 | Recruiting |
| Valkyrie Clinical Trials /ID# 271322 | Los Angeles | California | 90067 | Recruiting |
| FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816 | Oxnard | California | 93030 | Recruiting |
| Yale New Haven Hospital /ID# 271584 | New Haven | Connecticut | 06510 | Recruiting |
| Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899 | Jacksonville | Florida | 32256 | Recruiting |
| Ocala Oncology Center /ID# 273697 | Ocala | Florida | 34474 | Recruiting |
| Memorial Hospital West /ID# 270313 | Pembroke Pines | Florida | 33028 | Recruiting |
| Comprehensive Hematology Oncology /ID# 270422 | St. Petersburg | Florida | 33701-4732 | Recruiting |
| Florida Cancer Specialists - North /ID# 271995 | St. Petersburg | Florida | 33705 | Recruiting |
| Florida Cancer Specialists - East /ID# 271993 | West Palm Beach | Florida | 33401 | Recruiting |
| University Cancer & Blood Center /ID# 270969 | Athens | Georgia | 30607 | Recruiting |
| Northwest Georgia Oncology Centers /ID# 275374 | Marietta | Georgia | 30060 | Recruiting |
| Memorial University Medical Center /ID# 272467 | Savannah | Georgia | 31404 | Completed |
| Kaiser Permanente Moanalua Medical Center /ID# 272916 | Honolulu | Hawaii | 96819 | Recruiting |
| University of Illinois Hospital and Health Sciences System /ID# 275345 | Chicago | Illinois | 60607 | Recruiting |
| Illinois Cancer Specialists /ID# 274678 | Niles | Illinois | 60714 | Recruiting |
| Springfield Clinic - First /ID# 272576 | Springfield | Illinois | 62702 | Recruiting |
| Nebraska Hematology-Oncology /ID# 272970 | Lincoln | Nebraska | 68506 | Recruiting |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527 | Omaha | Nebraska | 68130 | Recruiting |
| Renown Regional Medical Center /ID# 273535 | Reno | Nevada | 89502 | Recruiting |
| Astera Cancer Care /ID# 272359 | East Brunswick | New Jersey | 08816-4096 | Recruiting |
| Regional Cancer Care Associates /ID# 270783 | Teaneck | New Jersey | 07666 | Recruiting |
| Montefiore Medical Center - Einstein Campus /ID# 277169 | The Bronx | New York | 10461 | Recruiting |
| Clinical Research Alliance - Westbury /ID# 270455 | Westbury | New York | 11590 | Recruiting |
| FirstHealth of the Carolinas- Speciality Center /ID# 272924 | Pinehurst | North Carolina | 28374 | Recruiting |
| Mercy Health - Perrysburg Cancer Center /ID# 270536 | Perrysburg | Ohio | 43551 | Recruiting |
| Genesis Healthcare System /ID# 273361 | Zanesville | Ohio | 43701 | Recruiting |
| Guthrie Robert Packer Hospital /ID# 270316 | Sayre | Pennsylvania | 18840 | Recruiting |
| Cancer Care Associates Of York /ID# 270971 | York | Pennsylvania | 17403 | Recruiting |
| Medical University of South Carolina /ID# 273272 | Charleston | South Carolina | 29425 | Recruiting |
| Saint Francis Cancer Center - Greenville /ID# 276368 | Greenville | South Carolina | 29607 | Recruiting |
| SCRI Oncology Partners /ID# 270162 | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Dallas - Worth Street /ID# 278947 | Dallas | Texas | 75246 | Recruiting |
| Texas Oncology - Northeast Texas /ID# 272000 | Tyler | Texas | 75702 | Recruiting |
| Community Cancer Trials Of Utah /ID# 276598 | Ogden | Utah | 84405 | Recruiting |
| Virginia Cancer Specialists - Fairfax /ID# 272004 | Fairfax | Virginia | 22031 | Recruiting |
| Medical Oncology Associates - Spokane /ID# 277172 | Spokane | Washington | 99208 | Recruiting |
| Northwest Medical Specialties Tacoma /ID# 270534 | Tacoma | Washington | 98405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06568939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06568939 live on ClinicalTrials.gov.